个人中心| | 帮助
高级检索
当前位置： 首页 > 详情页

Biodistribution and dosimetry of 177Lu-DOTA-IBA for therapy of bone metastases

| 认领 | 导出 | |

文献详情

资源类型：
Pubmed体系：
作者：
Li Hongmei[1,2,3] ; Pei Wenjie[1,2,3] ; Yang Xiqun[4] ; Qu Gengcuo[1,2,3] ; Hua Qingchu[1,2,3] ; Liu Lin[1,2,3] ; Wang Yudi[1,2,3] ; Xu Tingting[1,2,3] ; Chen Yue[1,2,3] ;
机构： [1]Department of Nuclear Medicine, The Afliated Hospital of Southwest Medical University, No 25 TaiPing St, Jiangyang District, Luzhou 646000, Sichuan, People’s Republic of China [2]Nuclear Medicine and Molecular Imaging Key Laboratory of Sichuan Province, Luzhou 646000, Sichuan, People’s Republic of China [3]Institute of Nuclear Medicine, Southwest Medical University, Luzhou 646000, Sichuan, People’s Republic of China [4]Department of Dermatology, Afliated Hospital of Southwest Medical University, Luzhou 646000, Sichuan, People’s Republic of China
出处：
DOI： 10.1186/s13550-024-01094-6
ISSN：

关键词： 177Lu-DOTA-IBA Dosimetry Biodistribution Bone metastasis Radionuclide therapy

摘要：
We designed and synthesized a novel bisphosphonate radiopharmaceutical (68 Ga- or 177Lu-labeled DOTA-ibandronate [68 Ga/177Lu-DOTA-IBA]) for the targeted diagnosis and treatment of bone metastases. The biodistribution and internal dosimetry of a single therapeutic dose of 177Lu-DOTA-IBA were evaluated using a series of single-photon emission computerized tomography (SPECT) images and blood samples. Five patients with multiple bone metastases were included in this prospective study. After receiving 1110 MBq 177Lu-DOTA-IBA, patients underwent whole-body planar, SPECT/CT imaging and venous blood sampling over 7 days. Dosimetric evaluation was performed for the main organs and tumor lesions. Safety was assessed using blood biomarkers.177Lu-DOTA-IBA showed fast uptake, high retention in bone lesions, and rapid clearance from the bloodstream in all patients. In this cohort, the average absorbed doses (ADs) in the bone tumor lesions, kidneys, liver, spleen, red marrow, bladder-wall, and osteogenic cells were 5.740, 0.114, 0.095, 0.121, 0.095, and 0.333 Gy/GBq, respectively. Although no patient reached the predetermined dose thresholds, the red marrow will be the dose-limiting organ. There were no adverse reactions recorded after the administration of 1110 MBq 177Lu-DOTA-IBA.Dosimetric results show that the ADs for critical organs and total body are within the safety limit and with high bone retention. It is a promising radiopharmaceutical alternative for the targeted treatment of bone metastases, controlling its progression, and improving the survival and quality of life of patients with advanced bone metastasis.© 2024. The Author(s).

基金：
This work is supported by the Program of Nuclear Medicine and Molecular Imaging Key Laboratory of Sichuan Province (2021LZXNYD-C02, 2021LZXNYDP03, 2021CXYZ02, 21ZD005 and U20A20384).
语种：
外文
PubmedID：
中科院(CAS)分区：
出版当年[2023]版：
大类 | 3 区 医学
小类 | 3 区 核医学
最新[2023]版：
大类 | 3 区 医学
小类 | 3 区 核医学
第一作者：
第一作者机构： [1]Department of Nuclear Medicine, The Afliated Hospital of Southwest Medical University, No 25 TaiPing St, Jiangyang District, Luzhou 646000, Sichuan, People’s Republic of China [2]Nuclear Medicine and Molecular Imaging Key Laboratory of Sichuan Province, Luzhou 646000, Sichuan, People’s Republic of China [3]Institute of Nuclear Medicine, Southwest Medical University, Luzhou 646000, Sichuan, People’s Republic of China
共同第一作者：
通讯作者：
通讯机构： [1]Department of Nuclear Medicine, The Afliated Hospital of Southwest Medical University, No 25 TaiPing St, Jiangyang District, Luzhou 646000, Sichuan, People’s Republic of China [2]Nuclear Medicine and Molecular Imaging Key Laboratory of Sichuan Province, Luzhou 646000, Sichuan, People’s Republic of China [3]Institute of Nuclear Medicine, Southwest Medical University, Luzhou 646000, Sichuan, People’s Republic of China
推荐引用方式(GB/T 7714)：
Li Hongmei,Pei Wenjie,Yang Xiqun,et al.Biodistribution and dosimetry of 177Lu-DOTA-IBA for therapy of bone metastases[J].EJNMMI Research.2024,14(1):30.doi:10.1186/s13550-024-01094-6.
APA：
Li Hongmei,Pei Wenjie,Yang Xiqun,Qu Gengcuo,Hua Qingchu...&Chen Yue.(2024).Biodistribution and dosimetry of 177Lu-DOTA-IBA for therapy of bone metastases.EJNMMI Research,14,(1)
MLA：
Li Hongmei,et al."Biodistribution and dosimetry of 177Lu-DOTA-IBA for therapy of bone metastases".EJNMMI Research 14..1(2024):30

相关文献

[1]68Ga/177Lu-labeled DOTA-TATE shows similar imaging and biodistribution in neuroendocrine tumor model. [2]Radionuclide therapy of bevacizumab-based PNA-mediated pretargeting [3]Alpha radionuclide-chelated radioimmunotherapy promoters enable local radiotherapy/chemodynamic therapy to discourage cancer progression [4]64Cu-labeled Melanin nanoparticles for PET/CT and radionuclide therapy of tumor. [5]Safety and Efficacy of Ga-68- or Lu-177-Labeled DOTA-IBA as a Novel Theranostic Radiopharmaceutical for Bone Metastases A Phase 0/I Study [6]Procoxacin bidirectionally inhibits osteoblastic and osteoclastic activity in bone and suppresses bone metastasis of prostate cancer [7]Angiocrine signals regulate quiescence and therapy resistance in bone metastasis. [8]Polymer composite microspheres loading 177Lu radionuclide for interventional radioembolization therapy and real-time SPECT imaging of hepatic cancer [9]Recent Advances in Prostate-Specific Membrane Antigen-Based Radiopharmaceuticals. [10]Nm23-H1 inhibits lung cancer bone-specific metastasis by upregulating miR-660-5p targeted SMARCA5.

资源点击量：43389 今日访问量：0 总访问量：3120 更新日期：2024-09-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持：重庆聚合科技有限公司 地址：成都市人民南路四段55号